多替拉韦 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "多替拉韦" in Chinese language version.

refsWebsite

Global rank Chinese rank

10web.archive.org

1^st place

1^st place

399^th place

208^th place

68^th place

209^th place

447^th place

581^st place

4^th place

5^th place

6^th place

4^th place

49^th place

81^st place

38^th place

9^th place

1viivhealthcare.ca

low place

low place

archive.org

British national formulary : BNF 69 69. British Medical Association. 2015: 429. ISBN 9780857111562.

drugs.com

Dolutegravir (Tivicay) Use During Pregnancy. Drugs.com. 2018-10-16 [2020-02-13]. （原始内容存档于2021-06-03）.
Dolutegravir Sodium Monograph for Professionals. Drugs.com. [2019-04-20]. （原始内容存档于2020-07-30）（英语）.

europa.eu

ema.europa.eu

Tivicay EPAR. European Medicines Agency (EMA). [2020-02-13]. （原始内容存档于2021-05-22）.
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 1-4 October 2018. European Medicines Agency (EMA). 2018-10-05 [2021-07-01]. （原始内容存档于2021-05-22）.

fda.gov

fda.gov

FDA approves new drug to treat HIV infection https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm364744.htmAugust 12, 2013 （页面存档备份，存于互联网档案馆）

accessdata.fda.gov

Drug Approval Package: Tivicay (dolutegravir) Tablets NDA #204790. U.S. Food and Drug Administration (FDA). 2013-09-13 [2020-06-12]. （原始内容存档于2021-03-28）.

nih.gov

dailymed.nlm.nih.gov

Tivicay- dolutegravir sodium tablet, film coated. DailyMed. 2019-10-24 [2020-02-13]. （原始内容存档于2021-05-22）.

reuters.com

U.S. FDA approves GlaxoSmithKline's HIV drug Tivicay. Reuters. 2013-08-12 [2020-02-13]. （原始内容存档于2021-05-22）.

viivhealthcare.ca

ViiV Healthcare receives approval for Tivicay (dolutegravir) in Canada for the treatment of HIV (PDF). [2013-11-11]. （原始内容 (PDF)存档于2013-11-12）.

web.archive.org

Dolutegravir (Tivicay) Use During Pregnancy. Drugs.com. 2018-10-16 [2020-02-13]. （原始内容存档于2021-06-03）.
Tivicay- dolutegravir sodium tablet, film coated. DailyMed. 2019-10-24 [2020-02-13]. （原始内容存档于2021-05-22）.
Tivicay EPAR. European Medicines Agency (EMA). [2020-02-13]. （原始内容存档于2021-05-22）.
Dolutegravir Sodium Monograph for Professionals. Drugs.com. [2019-04-20]. （原始内容存档于2020-07-30）（英语）.
FDA approves new drug to treat HIV infection https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm364744.htmAugust 12, 2013 （页面存档备份，存于互联网档案馆）
U.S. FDA approves GlaxoSmithKline's HIV drug Tivicay. Reuters. 2013-08-12 [2020-02-13]. （原始内容存档于2021-05-22）.
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 1-4 October 2018. European Medicines Agency (EMA). 2018-10-05 [2021-07-01]. （原始内容存档于2021-05-22）.
GSK wins priority status for new HIV drug in U.S. Reuters. 2013-02-16 [2013-02-18]. （原始内容存档于2013-02-27）.
Drug Approval Package: Tivicay (dolutegravir) Tablets NDA #204790. U.S. Food and Drug Administration (FDA). 2013-09-13 [2020-06-12]. （原始内容存档于2021-03-28）.
ViiV Healthcare receives approval for Tivicay (dolutegravir) in Canada for the treatment of HIV (PDF). [2013-11-11]. （原始内容 (PDF)存档于2013-11-12）.

yahoo.com

news.yahoo.com

GSK wins priority status for new HIV drug in U.S. Reuters. 2013-02-16 [2013-02-18]. （原始内容存档于2013-02-27）.